Mendelson Nicole L, Elliott Kayla R, Evans Krista E, Frisch Nora K, Abu Alfa Amer K
Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, VT, USA.
Department of Surgery, University of Vermont Medical Center, Burlington, VT, USA.
AME Case Rep. 2023 Jan 6;7:6. doi: 10.21037/acr-22-59. eCollection 2023.
The Food and Drug Administration (FDA)-approved submucosal injection of lifting agents such as ORISE has become a widespread, routine and standard practice in endoscopic mucosal resection and endoscopic submucosal dissection of gastrointestinal lesions. Lifting agent granulomas result from transformation of injected material into a mass-forming amorphous hyaline-like material eliciting a strong foreign body giant cell reaction. This report of three cases shows how lifting agent granulomas can act as potential clinical and gross mimickers of invasive adenocarcinoma.
Three cases were identified in a six-month span based on the histological presence of a lifting agent granuloma in a colonic/colorectal resection specimen with associated clinical, imaging and gross concern for invasive malignancy. Each case resulted in an escalation of clinical and surgical management due to the suspicion of an unresectable neoplastic process that was at least partially involved by an exuberant granulomatous reaction due to the utilization of a lifting agent. Colonic transmural involvement and sub-serosal vascular infiltration by the granulomas are described.
Lifting agent granulomas have become a routine endoscopic technique to help achieve full resection of flat/sessile colorectal polyps and early-stage cancers. This report confirms that these granulomas exhibit colonic transmural involvement. Sub-serosal blood vessel involvement is reported for the first time. It is important to recognize the unique characteristics of these new synthetic lifting agents. Their propensity to develop a mass-forming granulomatous reaction has the potential to mimic invasive adenocarcinoma clinically, radiologically and pathologically. This can significantly impact patient care and management both clinically and surgically.
美国食品药品监督管理局(FDA)批准的诸如ORISE等黏膜下注射提升剂,已成为胃肠道病变内镜黏膜切除术和内镜黏膜下剥离术中广泛应用的常规标准操作。提升剂肉芽肿是由注射材料转化为形成肿块的无定形透明样物质引起强烈的异物巨细胞反应所致。本报告的三例病例展示了提升剂肉芽肿如何在临床和大体形态上酷似浸润性腺癌。
在六个月的时间跨度内,通过对结肠/结直肠切除标本中提升剂肉芽肿的组织学检查,并结合相关临床、影像学表现以及对浸润性恶性肿瘤的大体形态学担忧,确定了三例病例。由于怀疑存在不可切除的肿瘤性病变,且至少部分病变因使用提升剂而出现了旺盛的肉芽肿反应,每例病例的临床和手术管理级别都有所升级。文中描述了肉芽肿对结肠壁全层的侵犯以及浆膜下血管浸润情况。
提升剂肉芽肿已成为帮助实现扁平/无蒂结直肠息肉和早期癌症完整切除的常规内镜技术。本报告证实这些肉芽肿可侵犯结肠壁全层,首次报告了浆膜下血管受累情况。认识这些新型合成提升剂的独特特征很重要。它们形成肿块性肉芽肿反应的倾向有可能在临床、放射学和病理学上酷似浸润性腺癌。这可能在临床和手术方面对患者的治疗和管理产生重大影响。